Advertisement.

ALNY Projected Dividend Yield

Alnylam Pharmaceuticals Inc ( NASDAQ : ALNY )

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics. Its marketed products include AMVUTTRA for hereditary transthyretin-mediated amyloidosis with polyneuropathy, ONPATTRO for polyneuropathy of hATTR amyloidosis, GIVLAARI for acute hepatic porphyria, OXLUMO for primary hyperoxaluria type 1, and Leqvio, developed with Novartis, for hypercholesterolemia or mixed dyslipidemia. The company also develops treatments for complement-mediated diseases, alpha-1 liver disease, and other conditions, including Cemdisiran, Belcesiran, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, and Fitusiran.

21 YEAR PERFORMANCE RESULTS

ALNY Dividend History Detail
ALNY Dividend News
ALNY Competitors News

# of Shares: 0

Closing Price: 234.56

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
2026	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000